Table 1.
Total Cohort n=297 | Number with Available Data | |
---|---|---|
Age, median (range) | 67 (37–91) | 297 |
Male, % | 68.0% | 297 |
Baseline renal dysfunction (creatinine clearance < 80 mL/min), % | 46.8% | 188 |
R/R, % | 95.6% | 297 |
Unmutated IGHV, % | 84% | 94 |
del(17p), % | 45% | 278 |
Prior lines of therapy, median (range) | 3 (0–15) | 297 |
Prior ibrutinib, % | 80% | 281 |
Venetoclax monotherapy, % | 80% | 296 |
TLS Risk | ||
Low, % | 40% | 295 |
Intermediate, % | 31.9% | 295 |
High, % | 28.1% | 295 |
TLS Rate | 8% | 296 |